Brii Biosciences Ltd. (7SS)
XMUN 
Summary
Brii Biosciences Ltd. (7SS) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Brii Biosciences Ltd. ever had a stock split?
Brii Biosciences Ltd. Profile
| Biotechnology Industry | Healthcare Sector | Dr. Zhi Hong Ph.D. CEO | XMUN Exchange | KYG1645A1094 ISIN |
| DE Country | 75 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
Brii Biosciences Limited is a biotechnological company focused on the discovery and development of novel therapies aimed at addressing infectious and central nervous system (CNS) diseases. Operating primarily within China and the United States, the company is on the forefront of developing innovative treatments that hold the potential to significantly impact public health. Founded in 2017, with its headquarters in Beijing, China, Brii Biosciences is making strides in research and development, striving towards advancements in the medical field with a particular emphasis on Hepatitis B, HIV, depressive disorders, and infections caused by multi-drug resistant bacteria.
Products and Services
- BRII-179, BRII-835, and BRII-877
- BRII-179
- BRII-732 and BRII-753
- BRII-296, BRII-297
- BRII-636, BRII-672, and BRII-693
- BRII-658
These are therapies in Phase 2 development targeting a functional cure for Hepatitis B (HBV). Each compound focuses on different mechanisms to combat HBV, showcasing Brii Biosciences' comprehensive approach to tackling this persistent viral infection.
A recombinant protein-based HBV immunotherapeutic candidate, currently in Phase 2. This development highlights the company’s efforts in stimulating the immune system to fight against HBV.
Developments for the treatment of HIV, with BRII-732 in Phase 1 clinical trial and BRII-753 in the preclinical stage. These products represent Brii Biosciences' commitment to finding effective treatments for HIV, aiming to improve the quality of life for those living with the virus.
These compounds are under development for the treatment of PPD/MDD (Postpartum Depression/Major Depressive Disorder), anxiety, and other depressive disorders. BRII-296 and BRII-297 show the company's focus on addressing the urgent need for new therapies in the CNS disease sector.
These products are targeted at treating multi-drug resistant/extensive drug resistant (MDR/XDR) gram-negative infections. The development of these antibiotics is crucial in the global fight against antibiotic-resistant bacteria, a major public health concern.
An oral treatment for patients with chronic NTM (Nontuberculous Mycobacteria) lung disease. BRII-658 illustrates Brii Biosciences’ dedication to providing solutions for lesser-known, yet debilitating, infectious diseases.
